GO:0001915 negative regulation of T cell mediated cytotoxicity: Immune Evasion Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0001915 describes any biological process that stops, prevents, or reduces the rate of T cell mediated cytotoxicity, a central mechanism of immune evasion in cancer and chronic infection.
• Tumors exploit this process through multiple mechanisms, including fibroblast-mediated T cell dysfunction driven by AEBP1, PD-L1 upregulation stabilized by OTUB2, and PGE2-mediated disruption of IL-2 signaling in tumor-infiltrating lymphocytes.
• Genome-wide CRISPR screens have identified cancer-intrinsic pathways that negatively regulate T cell killing, revealing therapeutic targets to restore immune surveillance.
• Fas-mediated off-target tumor killing represents a form of T cell cytotoxicity that can be harnessed therapeutically, and its negative regulation is critical for tumor immune escape.
• Microbiota-induced T cell plasticity can overcome negative regulation of cytotoxicity and enable immune-mediated tumor control.
• Understanding GO:0001915 is essential for developing strategies to enhance T cell immunotherapy, including checkpoint blockade and adoptive cell transfer.
Description
Negative regulation of T cell mediated cytotoxicity (GO:0001915) is a biological process that encompasses any mechanism which stops, prevents, or reduces the rate of cytotoxic T lymphocyte (CTL)-mediated killing of target cells. This process is fundamental to immune homeostasis and self-tolerance, but it is also hijacked by tumors and pathogens to evade immune destruction. The QuickGO definition states: 'Any process that stops, prevents, or reduces the rate of T cell mediated cytotoxicity.' This term is critical for researchers studying cancer immunology, autoimmune diseases, and infectious diseases, as it represents a key node where therapeutic intervention can restore or suppress T cell killing. T cell mediated cytotoxicity is executed primarily by CD8+ cytotoxic T cells and natural killer T cells, which recognize target cells through MHC class I-peptide complexes and induce apoptosis via perforin/granzyme and Fas/FasL pathways. Negative regulation of this process occurs at multiple levels: tumor cells can upregulate immune checkpoint ligands such as PD-L1, secrete immunosuppressive metabolites like PGE2, or recruit regulatory fibroblasts that impair T cell function. These mechanisms collectively create an immunosuppressive tumor microenvironment that limits the efficacy of immunotherapies. Recent advances in functional genomics, including genome-wide CRISPR screens, have systematically identified genes that negatively regulate T cell mediated cytotoxicity, providing a roadmap for combination therapies. Understanding the molecular players and pathways involved in GO:0001915 is therefore essential for developing next-generation immunotherapies that can overcome resistance to checkpoint blockade and adoptive T cell transfer.
negative regulation of T cell mediated cytotoxicity At A Glance
| GO ID | GO:0001915 |
|---|---|
| GO term | negative regulation of T cell mediated cytotoxicity |
| Ontology | biological_process |
| Synonym | inhibition of T cell mediated cytotoxicity; negative regulation of T-cell mediated cytolysis; downregulation of T cell mediated cytotoxicity |
| Major function | Suppression of cytotoxic T lymphocyte-mediated killing of target cells |
| Definition source | QuickGO |
| Related processes | Immune evasion, immune checkpoint regulation, tumor microenvironment immunosuppression |
| Key cell types | CD8+ T cells, regulatory T cells, tumor-associated fibroblasts, macrophages |
| Disease relevance | Cancer, chronic viral infections, autoimmune diseases |
What Is GO:0001915?
GO:0001915, negative regulation of T cell mediated cytotoxicity, is defined by QuickGO as any process that stops, prevents, or reduces the rate of T cell mediated cytotoxicity. This includes mechanisms that inhibit the ability of T cells (such as CD8+ cytotoxic T lymphocytes) to kill target cells, whether through direct cell-cell contact, cytokine secretion, or modulation of target cell susceptibility. The term encompasses both cell-intrinsic and cell-extrinsic regulatory pathways, including immune checkpoint signaling, metabolic suppression, and stromal cell-mediated inhibition.
Why Is negative regulation of T cell mediated cytotoxicity Important in Cell Biology?
GO:0001915 is critically important because it represents a central mechanism by which tumors and pathogens evade immune destruction, and it is a major barrier to successful cancer immunotherapy. Understanding how T cell mediated cytotoxicity is negatively regulated can reveal therapeutic targets to enhance T cell killing in cancer, or to suppress it in autoimmune diseases and transplant rejection. The process is highly relevant to the clinical success of immune checkpoint inhibitors, as many tumors resist anti-PD-1/PD-L1 therapy through alternative negative regulatory pathways.
• Tumors evade immune destruction by upregulating negative regulators of T cell cytotoxicity, such as PD-L1.
• Cancer-associated fibroblasts drive T cell dysfunction through AEBP1, contributing to immunosuppression.
• PGE2 produced in the tumor microenvironment inhibits TIL expansion by disrupting IL-2 signaling and mitochondrial function.
• Genome-wide CRISPR screens have identified multiple cancer-intrinsic genes that negatively regulate T cell killing.
• Fas-mediated off-target tumor killing is a form of T cell cytotoxicity whose negative regulation can limit immunotherapy efficacy.
• Microbiota-induced T cell plasticity can overcome negative regulation and enable tumor control.
• Irradiation combined with anti-PD-L1 treatment can synergistically promote antitumor immunity by overcoming negative regulation.
• Osteopontin mediates macrophage infiltration in glioblastoma and may contribute to T cell suppression.
• Understanding GO:0001915 aids in designing combination therapies to overcome resistance to checkpoint blockade.
• This process is also relevant to autoimmune diseases where excessive T cell cytotoxicity needs to be controlled.
What Happens During negative regulation of T cell mediated cytotoxicity?
Recognition of Target Cells and Initial T Cell Activation
In simple terms: T cells first need to recognize and bind to target cells to kill them.
T cell mediated cytotoxicity begins with the recognition of target cells by T cell receptors (TCRs) on CD8+ cytotoxic T lymphocytes. This recognition involves MHC class I molecules presenting peptides derived from intracellular proteins. Negative regulation can occur at this stage through downregulation of MHC class I on target cells or through checkpoint receptors such as PD-1 on T cells engaging PD-L1 on tumor cells, which dampens TCR signaling. Cancer-intrinsic evasion mechanisms often target this step, as revealed by genome-wide CRISPR screens.
Immune Checkpoint Signaling and PD-L1 Stabilization
In simple terms: Tumor cells can display 'don't eat me' signals that switch off T cells.
The PD-1/PD-L1 axis is a major negative regulatory pathway. Tumor cells upregulate PD-L1, which binds PD-1 on T cells and inhibits cytotoxic function. OTUB2 deubiquitinates and stabilizes PD-L1, thereby enhancing this negative regulation. Pharmaceutical targeting of OTUB2 sensitizes tumors to cytotoxic T cells, demonstrating the therapeutic potential of targeting this pathway. Similarly, irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity by blocking this negative regulation.
Metabolic and Soluble Factor-Mediated Suppression
In simple terms: The tumor environment can produce molecules that starve or exhaust T cells.
Prostaglandin E2 (PGE2) in the tumor microenvironment inhibits the expansion of tumor-infiltrating lymphocytes (TILs) by disrupting IL-2 signaling and mitochondrial function. This represents a metabolic mechanism of negative regulation of T cell mediated cytotoxicity. Additionally, osteopontin mediates macrophage infiltration in glioblastoma, which can contribute to an immunosuppressive microenvironment that limits T cell killing.
Stromal and Fibroblast-Mediated T Cell Dysfunction
In simple terms: Support cells around tumors can actively turn off T cells.
Cancer-associated fibroblasts (CAFs) can drive T cell dysfunction through secreted factors such as AEBP1. AEBP1 drives fibroblast-mediated T cell dysfunction in tumors, contributing to negative regulation of T cell mediated cytotoxicity. This highlights the role of the tumor stroma in suppressing immune responses and suggests that targeting stromal factors could restore T cell killing.
Microbiota and T Cell Plasticity
In simple terms: Gut bacteria can influence whether T cells stay active or become suppressed.
Microbiota-induced T cell plasticity can enable immune-mediated tumor control by overcoming negative regulatory signals. This indicates that the gut microbiome can modulate the balance between cytotoxic and regulatory T cell states, affecting the overall rate of T cell mediated cytotoxicity. Understanding these interactions may lead to microbiome-based therapies to enhance antitumor immunity.
Fas-Mediated Off-Target Killing and Its Regulation
In simple terms: T cells can kill innocent bystander cells, and this is tightly controlled.
Fas-mediated off-target tumor killing is a critical component of T cell immunotherapy, but it can also damage healthy tissues. Negative regulation of this process is essential to limit collateral damage. Upadhyay et al. demonstrated a critical role for Fas-mediated off-target tumor killing in T-cell immunotherapy, highlighting the need to understand its negative regulation to improve safety and efficacy.
Key Genes Involved in GO:0001915 negative regulation of T cell mediated cytotoxicity
The following genes and proteins are key players in the negative regulation of T cell mediated cytotoxicity, as supported by the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| AEBP1 | Drives fibroblast-mediated T cell dysfunction in tumors | Target for overcoming stromal immunosuppression |
| PD-L1 (CD274) | Immune checkpoint ligand that inhibits T cell function | Central target of checkpoint blockade therapy |
| OTUB2 | Deubiquitinase that stabilizes PD-L1 | Pharmaceutical target to sensitize tumors to T cells |
| Fas (CD95) | Mediates off-target tumor killing by T cells | Regulates T cell cytotoxicity and safety |
| PGE2 pathway (PTGS2) | Produces prostaglandin E2 that inhibits TIL expansion | Target to restore IL-2 signaling in TILs |
| IL-2 | Cytokine that promotes T cell expansion and function | Disrupted by PGE2 in tumor microenvironment |
| Osteopontin (SPP1) | Mediates macrophage infiltration in glioblastoma | Potential target to reduce immunosuppression |
| PD-1 (PDCD1) | Inhibitory receptor on T cells | Target of anti-PD-1 therapies |
| MHC class I | Presents antigens to T cells | Downregulation leads to immune evasion |
| CD8A | Marker of cytotoxic T cells | Key effector cell type in cytotoxicity |
| GZMB | Granzyme B, mediates target cell apoptosis | Effector molecule of T cell killing |
| PRF1 | Perforin, forms pores in target cells | Effector molecule of T cell killing |
| TGFB1 | Immunosuppressive cytokine | Contributes to negative regulation of T cell function |
| IL10 | Anti-inflammatory cytokine | Suppresses T cell cytotoxicity |
| VEGFA | Promotes angiogenesis and immunosuppression | Indirectly regulates T cell infiltration |
| CCL2 | Recruits macrophages to tumors | Mediates immunosuppression in glioblastoma |
| FOXP3 | Regulatory T cell marker | Regulatory T cells suppress cytotoxic T cells |
How Is negative regulation of T cell mediated cytotoxicity Regulated?
The negative regulation of T cell mediated cytotoxicity is controlled by multiple signaling pathways. The PD-1/PD-L1 axis is a major checkpoint, with OTUB2 stabilizing PD-L1 to enhance inhibition. PGE2 disrupts IL-2 signaling and mitochondrial function in TILs, representing a metabolic regulatory mechanism. Microbiota can modulate T cell plasticity, influencing the balance between cytotoxic and regulatory states. Additionally, irradiation can enhance anti-PD-L1 therapy by promoting antitumor immunity. These pathways are potential targets for therapeutic intervention to either enhance or suppress T cell cytotoxicity as needed.
negative regulation of T cell mediated cytotoxicity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| OTUB2 | Cancer immune evasion via PD-L1 stabilization | OTUB2 knockout tumor cells in syngeneic mouse models |
| AEBP1 | T cell dysfunction in tumors | AEBP1 knockout fibroblasts co-cultured with T cells |
| PTGS2 (COX-2) | PGE2-mediated inhibition of TIL expansion | PTGS2 knockout or inhibitor-treated tumor models |
| SPP1 (Osteopontin) | Glioblastoma macrophage infiltration | SPP1 knockout in glioblastoma mouse models |
| Fas (CD95) | Off-target tumor killing in immunotherapy | Fas knockout or point mutation in T cells |
Cancer Immune Evasion
Negative regulation of T cell mediated cytotoxicity is a hallmark of cancer immune evasion. Tumors upregulate PD-L1 through OTUB2-mediated stabilization, inhibiting T cell killing. Cancer-associated fibroblasts drive T cell dysfunction via AEBP1. PGE2 in the tumor microenvironment inhibits TIL expansion by disrupting IL-2 signaling. Genome-wide CRISPR screens have identified numerous cancer-intrinsic genes that negatively regulate T cell cytotoxicity, offering targets for combination immunotherapy.
Glioblastoma and Brain Tumors
In glioblastoma, osteopontin mediates macrophage infiltration and contributes to an immunosuppressive microenvironment that negatively regulates T cell cytotoxicity. Targeting osteopontin or its downstream pathways may enhance T cell-mediated tumor killing in glioblastoma.
Chronic Infections and Microbiota
Microbiota-induced T cell plasticity can overcome negative regulation of cytotoxicity and enable immune-mediated tumor control. This suggests that the gut microbiome influences the balance of T cell cytotoxicity in cancer and possibly chronic infections.
Autoimmune Diseases and Transplant Rejection
While negative regulation of T cell cytotoxicity is beneficial in cancer, it is detrimental in autoimmune diseases where excessive T cell killing causes tissue damage. Understanding these pathways can inform therapies to enhance negative regulation in autoimmunity.
From negative regulation of T cell mediated cytotoxicity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does OTUB2 regulate PD-L1 stability and T cell cytotoxicity? | OTUB2 knockout in tumor cells followed by co-culture with cytotoxic T cells |
| What is the role of AEBP1 in fibroblast-mediated T cell dysfunction? | AEBP1 knockout fibroblasts co-cultured with T cells or in vivo tumor models |
| How does PGE2 affect TIL expansion and function? | PTGS2 knockout mice or PGE2 receptor knockout T cells |
| Does osteopontin mediate macrophage infiltration in glioblastoma? | SPP1 knockout glioblastoma cells in orthotopic mouse models |
| What is the impact of Fas-mediated off-target killing? | Fas point mutation or knockout in T cells or tumor cells |
| Can microbiota modulate T cell cytotoxicity? | Germ-free mice or antibiotic-treated mice with tumor implants |
How to Study the negative regulation of T cell mediated cytotoxicity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Genome-wide CRISPR screen | Genes that regulate T cell killing | Identify negative regulators of cytotoxicity |
| Flow cytometry cytotoxicity assay | Percentage of dead target cells | Validate gene function in T cell killing |
| RNA sequencing | Transcriptional changes | Identify pathways altered by immunosuppressive factors |
| Proteomics (mass spectrometry) | Protein interactions and modifications | Study PD-L1 stabilization by OTUB2 |
| Immunohistochemistry | Protein expression in tissues | Assess AEBP1 or osteopontin in tumors |
| ELISA | Cytokine levels (e.g., IL-2, IFN-gamma) | Measure T cell function after PGE2 treatment |
| In vivo tumor models | Tumor growth and survival | Test efficacy of targeting negative regulators |
| Co-culture assays | T cell-mediated killing | Study fibroblast-mediated T cell dysfunction |
CRISPR Screens for Identifying Negative Regulators
Genome-wide CRISPR knockout screens in tumor cells co-cultured with cytotoxic T cells have identified genes that negatively regulate T cell mediated cytotoxicity. These screens typically use libraries targeting all human genes, followed by next-generation sequencing to identify enriched or depleted sgRNAs. Hits are validated by individual gene knockout and cytotoxicity assays.
Flow Cytometry and Cytotoxicity Assays
Flow cytometry-based cytotoxicity assays measure the ability of T cells to kill target cells. Target cells are labeled with fluorescent dyes, and co-culture with T cells is followed by propidium iodide or annexin V staining to quantify dead cells. This method is used to assess the impact of specific genes on T cell mediated cytotoxicity.
RNA Sequencing and Transcriptomics
RNA sequencing of tumor cells or T cells under conditions of negative regulation can reveal transcriptional programs that suppress cytotoxicity. For example, RNA-seq of TILs treated with PGE2 showed disruption of IL-2 signaling and mitochondrial function. This approach helps identify pathways and biomarkers associated with immune evasion.
Proteomics and Ubiquitination Analysis
Proteomic approaches, including mass spectrometry, can identify post-translational modifications such as ubiquitination that regulate key proteins like PD-L1. OTUB2 was shown to deubiquitinate PD-L1, and targeting this interaction sensitized tumors to T cells. Proteomics can uncover novel regulators of T cell cytotoxicity.
How CRISPR Can Be Used to Study GO:0001915 negative regulation of T cell mediated cytotoxicity
Knockout
CRISPR knockout of genes such as OTUB2, AEBP1, or PTGS2 can be used to study their role in negative regulation of T cell mediated cytotoxicity. For example, OTUB2 knockout in tumor cells leads to PD-L1 degradation and enhanced T cell killing. AEBP1 knockout fibroblasts show reduced T cell dysfunction. These models are essential for target validation.
Point Mutation
Point mutations can be introduced to study specific residues critical for protein function. For instance, mutating the deubiquitinase active site of OTUB2 can confirm its role in PD-L1 stabilization. Similarly, point mutations in Fas can dissect its role in off-target killing.
Knock-in
Knock-in of tagged proteins, such as PD-L1 with a fluorescent tag, allows real-time tracking of protein localization and stability. This can be combined with CRISPR screens to identify regulators of PD-L1 trafficking. Knock-in of reporter genes under the control of cytotoxicity-related promoters can also be used.
Overexpression
Overexpression of negative regulators such as PD-L1 or AEBP1 can be achieved by CRISPR activation (CRISPRa) or lentiviral transduction. This helps study their sufficiency in suppressing T cell cytotoxicity. For example, overexpression of PD-L1 in tumor cells inhibits T cell killing, which can be reversed by anti-PD-L1 antibodies.
How EDITGENE Supports negative regulation of T cell mediated cytotoxicity Research
Researchers studying negative regulation of T cell mediated cytotoxicity-related genes often need to determine whether a candidate gene is causally involved in suppressing T cell killing or whether it is merely a bystander. This requires precise genetic manipulation, which is best achieved through CRISPR-based cell model engineering. EDITGENE provides a comprehensive suite of services to support such studies.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of T cell mediated cytotoxicity research.
Frequently Asked Questions About negative regulation of T cell mediated cytotoxicity
What is GO:0001915?
GO:0001915 is the Gene Ontology term for 'negative regulation of T cell mediated cytotoxicity', defined as any process that stops, prevents, or reduces the rate of T cell mediated cytotoxicity.
What genes are involved in negative regulation of T cell mediated cytotoxicity?
Key genes include OTUB2, which stabilizes PD-L1, AEBP1, which drives fibroblast-mediated T cell dysfunction, PTGS2, which produces PGE2, and SPP1 (osteopontin), which mediates macrophage infiltration.
How do tumors evade T cell killing?
Tumors evade T cell killing by upregulating immune checkpoint ligands like PD-L1, secreting immunosuppressive factors like PGE2, and recruiting regulatory fibroblasts and macrophages.
What is the role of PD-L1 in negative regulation of T cell cytotoxicity?
PD-L1 binds to PD-1 on T cells, delivering inhibitory signals that suppress cytotoxic function. Its stabilization by OTUB2 enhances this negative regulation.
How can CRISPR screens identify negative regulators of T cell cytotoxicity?
Genome-wide CRISPR knockout screens in tumor cells co-cultured with T cells can identify genes whose loss enhances T cell killing, revealing negative regulators.
What is the impact of PGE2 on T cell mediated cytotoxicity?
PGE2 inhibits TIL expansion by disrupting IL-2 signaling and mitochondrial function, thereby negatively regulating T cell cytotoxicity.
What is AEBP1 and how does it affect T cells?
AEBP1 is a secreted protein that drives fibroblast-mediated T cell dysfunction in tumors, contributing to immune evasion.
Can microbiota influence negative regulation of T cell cytotoxicity?
Yes, microbiota-induced T cell plasticity can overcome negative regulation and enable immune-mediated tumor control.
What is Fas-mediated off-target tumor killing?
Fas-mediated off-target tumor killing is a mechanism by which T cells kill tumor cells, but it can also damage healthy tissues. Its negative regulation is important for safety.
How does irradiation affect anti-PD-L1 therapy?
Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity by overcoming negative regulation of T cell cytotoxicity.
Conclusion
GO:0001915, negative regulation of T cell mediated cytotoxicity, is a critical biological process that governs immune evasion in cancer and other diseases. The interplay between tumor cells, stromal cells, and T cells involves multiple checkpoints and metabolic pathways, many of which have been elucidated through CRISPR screens and functional studies. Targeting these negative regulators holds promise for enhancing immunotherapy efficacy. EDITGENE's comprehensive CRISPR services can accelerate research in this field by providing precisely engineered cell models and screening platforms.
References
- 1. Wang X et al.. 2025. AEBP1 drives fibroblast-mediated T cell dysfunction in tumors.. Nat Commun 16(1):8171 PMID: 40890191
- 2. Deng L et al.. 2014. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.. J Clin Invest 124(2):687-95 PMID: 24382348
- 3. Najar TA et al.. 2026. Microbiota-induced T cell plasticity enables immune-mediated tumour control.. Nature 651(8104):201-210 PMID: 41535459
- 4. Upadhyay R et al.. 2021. A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy.. Cancer Discov 11(3):599-613 PMID: 33334730
- 5. Lawson KA et al.. 2020. Functional genomic landscape of cancer-intrinsic evasion of killing by T cells.. Nature 586(7827):120-126 PMID: 32968282
- 6. Ren W et al.. 2024. Pharmaceutical targeting of OTUB2 sensitizes tumors to cytotoxic T cells via degradation of PD-L1.. Nat Commun 15(1):9 PMID: 38167274
- 7. Wei J et al.. 2019. Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target.. J Clin Invest 129(1):137-149 PMID: 30307407
- 8. Morotti M et al.. 2024. PGE(2) inhibits TIL expansion by disrupting IL-2 signalling and mitochondrial function.. Nature 629(8011):426-434 PMID: 38658764
